Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
29
Apr 2026
The AHA scientific statement calls for a life-course approach to brain health that integrates cognitive, emotional, behavioral, vascular, environmental, inflammatory, sleep, microbiome, and social factors. It highlights how early-life exposures, mental health, pollution, chronic inflammation, poor sleep, gut dysbiosis, and socioeconomic adversity may shape brain resilience and later-life cognitive decline.
29
Apr 2026
A new national survey reveals many women are unsure about when to start mammogram screening for breast cancer and believe they should start later than doctors recommend.
29
Apr 2026
Brain tumors cannot always be successfully treated with conventional therapies. A team from Empa and the hospital network HOCH Health Ostschweiz is therefore developing nanozymes that can attack cancer cells directly in the brain during tumor surgery.
29
Apr 2026
Scientists have discovered how cells decide when to respond to physical forces, potentially opening new avenues for tackling diseases such as cancer and fibrosis.